At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 149 enrolled
Drug / intervention
Imsidolimab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating Imsidolimab and Placebo for Hidradenitis Suppurativa. Completed, enrolled 149 participants across 34 sites in 4 countries.
Detailed Summary
Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesCanada, Georgia, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJul 2021
Primary CompletionJul 2022
Study CompletionDec 2022
TodayJul 2026
First PostedApr 23, 2021
Enrollment StartJul 7, 2021
Primary CompletionJul 15, 2022
Study CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.2 years ago
Interventions
Imsidolimabbiological
Humanized Monoclonal Antibody
Placebobiological
Placebo